Last updated: April 2026
Coluracetam (MKC-231) stands out in the racetam family for two reasons: it's among the most potent HACU (high-affinity choline uptake) upregulators in the class, and users consistently report a distinct visual enhancement effect — sharper colors, better contrast — not found with other racetams. It's also the only racetam studied in an MDD trial.
HACU upregulation is coluracetam's core mechanism — but the visual enhancement effect has generated significant community interest and deserves its own explanation.
HACU is the transport mechanism that moves choline into neurons for acetylcholine (ACh) synthesis. It's the rate-limiting step — the bottleneck for ACh production. Coluracetam upregulates both the number and efficiency of these transporters. Result: more choline enters neurons, more ACh is synthesized. This is why coluracetam has potent cholinergic effects even at low doses.
Acetylcholine plays a significant role in visual processing — particularly in the lateral geniculate nucleus and visual cortex, where it modulates contrast sensitivity and feature detection. Coluracetam's strong HACU upregulation may enhance cholinergic activity in visual processing centers. Users report sharper edges, more vivid colors, and improved contrast sensitivity. This is primarily anecdotal but consistently reported.
Acetylcholine has complex roles in mood regulation. The cholinergic hypothesis of depression posits that excess cholinergic activity contributes to depressive states — but the relationship is more nuanced. Coluracetam in the MDD trial may work by normalizing dysfunctional cholinergic signaling specifically in limbic circuits. This is distinct from serotonergic antidepressants.
Like most racetams, coluracetam also modulates AMPA receptors (positive allosteric modulation). This contributes to memory formation, LTP (long-term potentiation), and the general cognitive effects associated with the racetam class. The dual action — HACU upregulation + AMPA PAM — is why coluracetam has both acute (visual, mood) and longer-term (memory consolidation) effects.
The only published human clinical data for coluracetam — a Phase 2a trial in treatment-resistant major depressive disorder.
Based on the MDD trial, community use reports, and the general racetam safety profile.
Critical choline support and complementary compounds for coluracetam stacking.
Coluracetam is not approved by the FDA for any indication. This content is educational only and does not constitute medical advice. Do not use coluracetam as a substitute for prescribed antidepressant treatment. Consult a physician before use.